Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00961714
Other study ID # 08-02-A
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date August 2009
Est. completion date July 2013

Study information

Verified date April 2022
Source Alphatec Spine, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The OsseoFix Spinal Fracture Reduction System facilitates the treatment of spinal fractures by providing internal fixation and stabilization using a titanium implant in conjunction with OsseoFix+™ polymethylmethacrylate (PMMA) bone cement. The purpose of the study is to provide reasonable assurance on safety and effectiveness of the OsseoFix Spinal Fracture Reduction System for market release approval in the US. This investigational device is intended to restore biomechanical integrity to a vertebral body that has suffered a painful compression fracture in the thoracic or lumbar spine between levels T6 and L5.


Description:

This is a prospective, multi-center clinical study designed to evaluate safety and effectiveness of the OsseoFix Spinal Fracture Reduction System used with PMMA bone cement relative to the clinical expectations for treatment of vertebral compression fractures (VCFs). The study will be conducted at up to 15 investigational centers in the United States in 115 (up to 125) subjects with one or two vertebral compression fractures between levels T6 and L5 implanted with the investigational device(s). Baseline screening will be completed to determine eligible subjects. VCFs will be confirmed by magnetic resonance imaging (MRI), or by a CT / bone scan. These diagnostic tests will be utilized to confirm that there are no retropulsed bone fragments. Subjects who meet all inclusion criteria and do not have any exclusion criteria will be scheduled to receive the OsseoFix Spinal Fracture Reduction System. Subjects that are enrolled will be implanted with the OsseoFix Spinal Fracture Reduction System through a postero-lateral approach to the anterior vertebral body using instruments specifically designed for this procedure. Radiographs will be taken at each follow-up visit, including baseline and post-operatively. Subject's perception of pain will be assessed using the Visual Analogue Scale (VAS). Functional outcomes will be measured using the Oswestry Disability Index (ODI) and Short Form- 36 (SF-36) questionnaires as well as their neurologic status. The VAS, ODI, SF-36 and neurologic status will be measured at baseline, 4-week, 3-month, 6-month and 12-month follow-up visits. Overall patient-satisfaction will be evaluated at all post-implant scheduled follow-up visits. Adverse event will be the recorded in all scheduled and non-scheduled visits. The endpoint analysis will be performed and submitted when all implanted subjects have completed their 12-months follow-up.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date July 2013
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 105 Years
Eligibility Inclusion Criteria: - 5o years of age. - Legal US citizen with ability to read and write. - Acute painful fracture (=2 months) between T6 to L5 as evidenced by plain radiography, CT / Bone scan, and/or magnetic resonance imaging. - Subject is... - Non-Standard Treatment: - Inability to tolerate prolonged conservative care due to intractable pain (VAS 70/100) with maximum tolerated medication for at least 2 weeks, but less than 6 weeks; OR - Inability to tolerate prolonged immobilization due to other comorbid conditions aggravated by immobility for at least 2 weeks, but less than 6 weeks; OR - Intolerance of or adverse reaction to available pain medications for at least 2 weeks, but less than 6 weeks; OR - Hospitalization secondary to pain for at least 2 weeks, but less than 6 weeks. - Standard Treatment: - Has undergone at least 6 weeks of conservative care. - Have a self assessment VAS score = 50 mm at the Baseline visit. - Have 30% or greater disability score on ODI at the Baseline visit. - Anterior wedge deformity with no less than 5% and no more than 75% loss of anterior cortical height as compared to the posterior cortical height of the same vertebral body. - Bone mineral density (BMD) T-score of -1.5 or less, as determined by a DEXA scan. - Intact posterior cortical vertebral body wall. - Type A compression fractures according to AO classification of spinal vertebral fractures. - If a transpedicular approach is utilized the pedicle diameter must be equal to or greater than 6.5 mm; however, if an extrapedicular approach is utilized there is not a minimum pedicle width requirement. - Subject is willing and able to provide informed consent and agrees to release medical information for purposes of this study (HIPAA authorization) and to return for scheduled follow-up evaluations. Exclusion Criteria: - Significant vertebral collapse defined as more than 75% of original vertebral height or less than 5% or a burst or pedicle fracture with posterior cortical wall disruption. - Presence of healed fracture at the intended treatment level(s) based on a CT / bone scan or MRI. - Compression fractures requiring treatment at 3 or more levels. - Spinal/Foraminal canal compromised. - Significant deformity/instability indicated by: - Segmental kyphosis > 30 degrees, or - translation > 4 mm. - VAS back pain score of < 50 mm. - ODI score of < 30%. - Have a documented active systemic or local infection, such as AIDS, hepatitis, with a WBC greater than 11.5 and a temperature greater than 101.5°F. - Spinal surgery in the thoracic and/or lumbar region within the past year - Previous kyphoplasty or vertebroplasty at involved level or level above or below treated level. - Spinal arthrodesis within 2 adjacent levels of fracture. - Non-ambulatory prior to fracture. - Greater than Grade 1 spondylolisthesis at level of fracture. - Scoliosis > 10 degrees. - BMI > 40. - Severe cardiopulmonary deficiencies. - Pregnant. - Type I or II diabetes without controlled A1C level. - Achondrogenesis disorders. - Active malignancy, hemangiomas at the operative level(s), or multiple myeloma. - No generally accepted medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy with a threshold for INR at 1.5 or less, and platelet count 100,000. - A life expectancy less than the study duration or undergoing palliative care. - Trauma injuries aside from vertebral compression fracture(s). - Injuries that violate the posterior vertebral cortex and/or posterior column. - Active litigation. - Currently on workman's compensation. - Autoimmune disorders. - Non-spine pain that requires daily Opioids. - Systemic long-term steroid use - greater than 6 months. - Active multiple sclerosis or neurologic deficit caudal to fracture. - Currently an alcohol, solvent, or drug abuser. - Psychiatric or cognitive impairment that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements. - History of allergies to any of the device components including but not limited to commercially pure titanium, titanium alloy, polymethylmethacrylate or Zirconium Oxide (ZrO2) - Incarcerated. - Are currently participating in another investigational study. - Having had another device implanted in the thoracic and/or lumbar area that would interfere with the surgical approach, study device, or follow-up evaluations.

Study Design


Intervention

Device:
OsseoFix Spinal Fracture Reduction System
All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.

Locations

Country Name City State
United States Boulder Neurosurgery Associates Boulder Colorado
United States Neurospine Solutions, PC Bristol Tennessee
United States Orthopaedic Associates of the Greater Lehigh Valley Easton Hospital Easton Pennsylvania
United States Clinical Radiology of Oklahoma Edmond Oklahoma
United States NeuroSpine Institute, LLC Eugene Oregon
United States Lyerly Neurosurgery Jacksonville Florida
United States Scripps La Jolla California
United States South Denver Neurosurgery Littleton Colorado
United States Jewish Hospital for Advanced Medicine Louisville Kentucky
United States Southwestern Orthopedic Center Savannah Georgia
United States SIU Phyysicians and Surgeons Division of Orthopaedics and Rehabilitation Springfield Illinois

Sponsors (1)

Lead Sponsor Collaborator
Alphatec Spine, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Back Pain Improvement at 12 Months Back pain improvement is defined as a reduction in VAS score of = 20mm at 12 months from baseline 12 months
Primary Percentage of Participants With Functional Disability Improvement at 12 Months Functional disability improvement is defined as a reduction in ODI score by = 15 points at 12 months from baseline. 12 months
Primary Absence of Device Related Subsequent Interventions or Re-treatment at the Study Treated Levels 12 months
Secondary Change in Pain at 12 Months as Presented by VAS, When Compared to Baseline Pain measurements determined by Visual Analog Scale (VAS) on a 100mm scale with, 0=no pain at all, to 100=worse possible pain. 12 months
Secondary Functional Disability Change at 12months From Baseline as Determined by ODI Improvement in functional disability as determined by ODI on a scale of 0-50, with 0=no disability at all to 50=complete disability 12 months
Secondary Any Cement Extravasation Before Discharge 12 months
See also
  Status Clinical Trial Phase
Completed NCT01482793 - A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures N/A
Recruiting NCT05337696 - Circumferential Vertebral Reconstruction of Osteoporotic Compression Fractures Using a Novel Bipedicular Peek Implant N/A
Completed NCT02657265 - SpineJack® Versus Conservative Treatment Study (SPICO Study) N/A
Terminated NCT00819832 - Anderson Circulating Tumor Cell Burden (CTCB) Study Phase 4
Completed NCT02608801 - Prediction and Secondary Prevention of Fractures
Completed NCT02461810 - Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques N/A
Terminated NCT02370628 - Vertebroplasty In The Treatment Of Acute Fracture Trial - The VITTA Trial N/A